Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $36.6M fell 15.8% year over year, behind the -11.7% change in trailing-twelve-month research & development. Sequentially, it fell 29.9% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Research & development amounted to 440763.9% of revenue in FY2025, up 159447.5 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -15.8% toward the trailing-twelve-month pace of -11.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 158.68M USD
- Year-over-year change
- -7.5%
- 4-year CAGR
- +3.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 158.68M | -7.5% |
| FY2024 | 2024-12-31 | 171.6M | -6.2% |
| FY2023 | 2023-12-31 | 182.95M | +14.9% |
| FY2022 | 2022-12-31 | 159.19M | +14.8% |
| FY2021 | 2021-12-31 | 138.69M | — |
Research & Development vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.7% is the 6th highest of 10, against a peer median of -6.9%.
- Research & development amounts to 489780.6% of revenue for LYEL, versus a peer median of 1409.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.7M USD | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $151.83M USD | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $151.01M USD | +44.8% | +53.7% | — | |
| LTM Mar 2026 | $129.09M USD | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $126.01M USD | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $66.19M USD | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
| LTM Mar 2026 | $20.65M USD | -58.3% | -18.4% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $20.4M USD | +3.6% | +29.8% | 254962.5% |
| LTM Mar 2026 | $18.45M USD | -6.9% | -13.3% | 8.6% | |
| Peer median (excluding LYEL) | — | -6.9% | +10.9% | 1409.6% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.65M | 84.68M | 130K | 61K | 36K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.54M |
| Gross Profit | 10.65M | 84.68M | 130K | 61K | (11.5M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| Research & Development | 138.69M | 159.19M | 182.95M | 171.6M | 158.68M |
| Selling, General & Admin | 89.06M | 117.31M | 66.98M | 52.04M | 45.14M |
| Operating Expenses | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M |
| Depreciation & Amortization | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M |
| EBITDA | (236.6M) | (165.1M) | (214.38M) | (200.64M) | (262.91M) |
| EBITDA Margin | -2221.5% | -195.0% | -164909.2% | -328923.0% | -730302.8% |
| Operating Income | (214.78M) | (187.06M) | (247.01M) | (358.76M) | (203.77M) |
| Operating Margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -566038.9% |
| Interest Income | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (35.44M) | 3.94M | 12.38M | 15.76M | (70.67M) |
| Income Before Tax | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Pre-Tax Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Net Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (Basic) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| EPS (Diluted) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| Weighted Avg Shares | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
| Weighted Avg Shares (Diluted) | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.